Health Catalyst (NASDAQ:HCAT) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Health Catalyst (NASDAQ:HCAT) posted its quarterly earnings results on Wednesday. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), Briefing.com reports. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.49%. The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same period in the prior year, the business earned ($0.22) earnings per share. Health Catalyst’s revenue was up 3.5% compared to the same quarter last year. Health Catalyst updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded down $0.62 during trading on Friday, hitting $8.24. The company had a trading volume of 674,743 shares, compared to its average volume of 485,899. The company has a fifty day simple moving average of $8.07 and a two-hundred day simple moving average of $7.14. Health Catalyst has a one year low of $5.42 and a one year high of $11.41.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JPMorgan Chase & Co. boosted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler dropped their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Evercore ISI lifted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Royal Bank of Canada increased their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and a consensus target price of $11.64.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares in the company, valued at $998,613. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the sale, the chief operating officer now directly owns 129,690 shares of the company’s stock, valued at $998,613. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,396 shares of company stock valued at $266,280. 2.50% of the stock is currently owned by insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.